Filsuvez 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification
Decision 
Information 
1 issued on 
Issued2 / 
affected3  
amended 
on 
II/0006 
Update of sections 4.8 and 5.1 of the SmPC in order 
14/12/2023 
25/01/2024 
SmPC and 
Please refer to Scientific Discussion 
to update clinical information based on final results 
Annex II 
‘Filsuvez/H/C/005035/II/0006’. 
from study EASE (BEB-13); this is a double-blind, 
randomised, placebo (vehicle) controlled trial to 
evaluate efficacy and safety of birch bark extract on 
top of standard of care in paediatric and adult 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
 
 
 
patients with epidermolysis bullosa. In addition, the 
MAH took the opportunity to introduce minor 
changes to the PI. 
C.I.4 - Change(s) in the SPC, Labelling or PL due to 
new quality, preclinical, clinical or pharmacovigilance 
data 
N/0008 
Minor change in labelling or package leaflet not 
17/10/2023 
25/01/2024 
PL 
connected with the SPC (Art. 61.3 Notification) 
PSUSA/10446
Periodic Safety Update EU Single assessment - birch 
31/08/2023 
n/a 
PRAC Recommendation - maintenance 
/202301 
bark extract (centrally authorised products) 
IA/0005 
A.4 - Administrative change - Change in the name 
13/04/2023 
n/a 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
PSUSA/10446
Periodic Safety Update EU Single assessment - birch 
09/02/2023 
n/a 
PRAC Recommendation - maintenance 
/202207 
bark extract (centrally authorised products) 
IAIN/0003 
B.II.b.1.a - Replacement or addition of a 
20/10/2022 
n/a 
manufacturing site for the FP - Secondary packaging 
site 
IB/0001/G 
This was an application for a group of variations. 
04/10/2022 
09/10/2023 
SmPC, 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
Labelling and 
PL 
Page 2/3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.2 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change outside 
the range of the currently approved pack sizes 
B.II.e.5.a.2 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change outside 
the range of the currently approved pack sizes 
Page 3/3 
 
 
 
 
 
 
 
